An Empirical Study Comparing Industry Segments as Regards Organisation Management in Open Innovation - Based on a Questionnaire of the Pharmaceutical Industry and IT Component Industry Segment
Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 33122
An Empirical Study Comparing Industry Segments as Regards Organisation Management in Open Innovation - Based on a Questionnaire of the Pharmaceutical Industry and IT Component Industry Segment

Authors: F. Isada, Y. Isada

Abstract:

The aim of this research is to clarify the difference by industry segment or product characteristics as regards organisation management for an open innovation to raise R&D performance. In particular, the trait of the pharmaceutical industry is defined in comparison with IT component industry segment. In considering open innovation, both inter-organisational relation and the management in an organisation are important issues. As methodology, a questionnaire was conducted. In conclusion, suitable organisation management according to the difference in industry segment or product characteristics became clear.

Keywords: Empirical study, industry segment, open innovation, product-development organisation pattern.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1107511

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1740

References:


[1] J.W. Scannell, A. Blanckley, H. Boldon, and B. Warrington, “Diagnosing the decline in pharmaceutical R&D efficiency,” Nature Reviews Drug Discovery, vol. 11, pp.191–200, 2012.
[2] Y. Suwa, “A structural change of pharmaceuticals industry segment: four shifts and three functions which bear futures”, Business Perspective from Roland Berger, vol. 87, pp.1–4, Apr. 2013.
[3] H. W. Chesbrough, “The era of open innovation”, Managing Innovation and Change, vol. 127, no. 3, pp. 34–41, 2006.
[4] K. Motohashi, Y. Ueda, and M. Mino, “The new tide of Japanese firm about the open innovation: The result and consideration of the interview survey to leading makers”, RIETI Policy Discussion Paper Series, 12-P-015, pp. 1–17, 2012.
[5] R. Kneller, “The importance of new companies for drug discovery: origins of a decade of new drugs,” Nature Reviews Drug Discovery, vol. 9, pp.867–882, 2010.
[6] Japan Health Sciences Foundation, Open innovation in drug development, HS report No.78, 2013.
[7] M. Sakurai and H. Kakihara, "Directed to an expansion of Japanese pharmaceutical industry", Pharmacia, vol. 49, pp. 965–969, 2013.
[8] K. Kakita, "Product lifecycle management (first volume)", International Drug Information, vol. 26, pp. 22–25 November, 2001.
[9] H. Yoshino, "DDS as part of product lifecycle management", Drug Delivery System, vol. 20, no. 6, pp.648–655, 2005.
[10] L. Haupt, “Vertical integration and strategic sourcing in the biopharmaceutical industry”, dissertation, Massachusetts Institute of Technology, 2005.
[11] A. S. C. A. D Esteves, “Technology market transfer plan-launch of DELIVES to EU market”, dissertation, Universidde Nova de Lisbosa, 2011.
[12] K. B. Clark, and T. Fujimoto, “Product development in the world auto industry”, Brookings Papers on Economic Activity, pp. 729–771, 1991.
[13] M. Iansiti, “Technology integration: Managing technological evolution in a complex environment”, Research Policy, vol. 24, pp.521–542, 1995.
[14] K. M. Eisenhardt and B. N. Tabrizi, “Accelerating adaptive process: Product innovation in the global computer industry”, Administrative Science Quarterly, vol. 40, pp. 84–110, 1995.
[15] K. Kuwajima, “Organizational capability in the research-and-development process of pharmaceutical products”, Organizational Science, vol. 33, no. 2, pp. 88–104, 1999.
[16] H. A Simon, “The science of design: creating the artificial”, Design Issues, pp.67–82, 1988.
[17] T. Fujimoto, and M. Yasumoto, “A Comparison of Effective Product Development Pattern across Multi-Industries -Results of a Questionnaire Survey in 203 Product Development Organizations”, CIRJE-J-7, 1998.
[18] W. M. Cohen and D. A. Levinthal, “Absorptive capacity: a new perspective on learning and innovation”, Administrative Science Quarterly, pp. 128–152, 1990.
[19] R. Henderson and I. Cockburn, “Measuring competence? Exploring firm effects in pharmaceutical research”, Strategic Management Journal, vol. 15, pp. 63–84, 1994.
[20] D. Aloini, and A. Martini, “Exploring the exploratory search for innovation: a structural equation modelling test for practices and performance”, International Journal of Technology Management, vol. 61, no.1, pp.23–46, 2013.
[21] Y. Hamaoka, "The determinant factor of the results of inbound, outbound open innovation", in Annual Conference Proceedings of Japan Society for Science Policy and Research Management, 27, 2012, pp.1017–1022.
[22] N. Takahashi, K. Kuwajima, and M. Tamada, "Research-and-development performance and gatekeeper", CIRJE-J-67, 2002.
[23] H. Huang, “Technological learning and technological innovation creation: An empirical analysis of biotechnology R&D Teams”, Journal of Engineering Science and Technology Review, vol. 6, no. 2, pp.120–124, 2013.
[24] A. Oke, D. I. Prajogo, and I. Jayaram, “Strengthening the innovation chain: The role of internal innovation climate and strategic relationships with supply chain partners”, Supply Chain Management, vol. 49, no. 4, pp. 43–58, 2013.
[25] H. Shiraishi, "The essence of dynamic capability – case study of Kao and Dai Nippon Printing”, Journal of Information and Management, vol. 29, no. 4, pp. 72–83, 2009.
[26] A. Takeshi, “The division of work between companies and innovation: From the viewpoint of a division of knowledge", IIR Working Paper, pp. 1–10, Sep. 2001.